Transactions
Dec. 19, 2000
Latham & Watkins: GENOMICS DEVELOPER PLANS FOR INITIAL PUBLIC OFFERING
Santa Clara's diaDexus Inc. has filed for an initial public offering valued at $100 million. DiaDexus, founded by genomics companies SmithKline Beecham Corp. and Incyte Genomics Inc. in 1997, discovers and develops novel genomic biomarkers that have the potential of detecting diseases in individuals before they experience any symptoms. The company has 37 biomarkers in development, most of which will target cancer detection.




DiaDexus, founded by genomics companies SmithKline Beecham Corp. and Incyte Genomics Inc. in 1997, discovers and develops novel genomic biomarkers that have the potential of detecting diseases in individuals before they experience any symptoms. The company has 37 biomarkers in developme...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In